Follow-up (FU) policy after treatment for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL); The patients view

被引：0
|
作者：
Watson, AJ
Pool, C
Radford, JA
机构：
[1] Christie Hosp, Dept Med Oncol, Manchester M20 4BX, Lancs, England
[2] Christie Hosp, Dept Psychol Med, Manchester M20 4BX, Lancs, England
来源：
BRITISH JOURNAL OF CANCER | 1999年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
49
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [1] Anticipation occurs in familial Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
    Wiernik, PH
    Wang, SQ
    Hu, XP
    Marino, P
    BLOOD, 1997, 90 (10) : 3964 - 3964
  • [2] Thymic residual masses in adult patients with Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD).
    Tartas, N
    Chacón, C
    Domenichini, E
    Pascuccelli, H
    Sporn, V
    Mazzucco, J
    Korin, J
    Barazzutti, L
    Ferro, H
    Busso, P
    Foncuberta, C
    Kusminsky, G
    Chacón, R
    Avalos, JS
    BLOOD, 1999, 94 (10) : 255B - 255B
  • [3] Whole-body positron emission tomography (PET) for staging, response evaluation and follow-up of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
    Jerusalem, G
    Fassotte, MF
    Paulus, P
    Rigo, P
    Fillet, G
    BLOOD, 1995, 86 (10) : 2125 - 2125
  • [4] Analysis of ploidy and proliferative activity in childhood non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD)
    Coad, NAG
    Jones, TJ
    Muir, KR
    Parkes, SE
    Smith, K
    Raafat, F
    Mann, JR
    PEDIATRIC PATHOLOGY & LABORATORY MEDICINE, 1997, 17 (06): : 893 - 902
  • [5] Long term follow-up of CEOP in the treatment of HIV related non-Hodgkin's lymphoma (NHL)
    Davis, AJ
    Goldstein, D
    Milliken, S
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1998, 28 (01): : 28 - 32
  • [6] Standardized uptake value (SUV) for staging of non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD).
    Cortés-Blanco, A
    Martínez-Lázaro, R
    Zhuang, HM
    Alavi, AA
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 279P - 279P
  • [7] ASHAP salvage therapy for recurrent and refractory Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
    Hanel, M
    Hoffknecht, MM
    Peters, SO
    Fiedler, F
    Hanel, A
    Kruger, WH
    Zeller, W
    Braumann, D
    Illiger, HJ
    Metzner, B
    Schubert, JC
    Schmitz, N
    Weh, HJ
    Kroger, N
    Zander, AR
    BLOOD, 1997, 90 (10) : 4559 - 4559
  • [8] INCIDENCE AND FACTORS INFLUENCING STEM CELL MOBILIZATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA (NHL) AND HODGKIN'S DISEASE (HD)
    Popat, U.
    Saliba, R.
    Ahlawat, S.
    Okoroji, G. J.
    Alousi, A.
    Anderlini, P.
    Andersson, B.
    de Lima, M.
    Jones, R.
    Kebriaei, P.
    Korbling, M.
    Nieto, Y.
    Qazilbash, M.
    Shpall, E. J.
    Khouri, I
    Giralt, S.
    Champlin, R.
    Hosing, C.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 37 - 38
  • [9] Clinical relevance of angiogenesis-modulating factors in patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
    Giles, FJ
    Vose, JM
    Manshouri, T
    Dey, A
    Bociek, G
    Bierman, PJ
    Keating, M
    Armitage, JO
    Albitar, M
    BLOOD, 2001, 98 (11) : 805A - 805A
  • [10] Autologous transplants followed by mini-allografts for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).
    Carella, AM
    Corsetti, MT
    Lerma, E
    Cavaliere, M
    BLOOD, 2000, 96 (11) : 407A - 407A
12345